1
13.59
-0.03 (-0.22%)
| Previous Close | 13.62 |
| Open | 13.47 |
| Volume | 2,309,572 |
| Avg. Volume (3M) | 3,820,050 |
| Market Cap | 1,673,391,104 |
| Price / Sales | 2.39 |
| Price / Book | 2.03 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | -25.14% |
| Operating Margin (TTM) | -31.33% |
| Diluted EPS (TTM) | -1.30 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Total Debt/Equity (MRQ) | 11.33% |
| Current Ratio (MRQ) | 5.37 |
| Operating Cash Flow (TTM) | 56.74 M |
| Levered Free Cash Flow (TTM) | 95.16 M |
| Return on Assets (TTM) | -12.43% |
| Return on Equity (TTM) | -22.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bullish | Mixed |
| Health Information Services (Global) | Bullish | Mixed | |
| Stock | 10x Genomics, Inc. | Bullish | Bearish |
AIStockmoo Score
0.1
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -1.5 |
| Average | 0.13 |
|
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 1.93% |
| % Held by Institutions | 101.82% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Venrock Management Vi, Llc | 30 Sep 2024 | 2,106,757 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 17.00 (Morgan Stanley, 25.09%) | Buy |
| Median | 15.00 (10.38%) | |
| Low | 13.00 (UBS, -4.34%) | Hold |
| 13.00 (B of A Securities, -4.34%) | Hold | |
| Average | 14.60 (7.43%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 12.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 11 Sep 2025 | 15.00 (10.38%) | Hold | 13.06 |
| Morgan Stanley | 12 Aug 2025 | 17.00 (25.09%) | Buy | 12.81 |
| Barclays | 08 Aug 2025 | 15.00 (10.38%) | Buy | 12.29 |
| 24 Jun 2025 | 13.00 (-4.34%) | Buy | 10.89 | |
| UBS | 08 Aug 2025 | 13.00 (-4.34%) | Hold | 12.29 |
| B of A Securities | 26 Jun 2025 | 13.00 (-4.34%) | Hold | 11.70 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Sep 2025 | Announcement | CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics |
| 27 Aug 2025 | Announcement | 10x Genomics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference |
| 19 Aug 2025 | Announcement | 10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis |
| 07 Aug 2025 | Announcement | 10x Genomics Reports Second Quarter 2025 Financial Results |
| 07 Aug 2025 | Announcement | 10x Genomics to Acquire Scale Biosciences |
| 17 Jul 2025 | Announcement | 10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery |
| 10 Jul 2025 | Announcement | 10x Genomics to Report Second Quarter 2025 Financial Results on August 7, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |